TheTechno Optimist.

OlpasiranAmgen—Amgen shares fall after the pelacarsen result and a BMO downgradeOlpasiranAmgen—Rival Lp(a) drug pelacarsen misses its heart-outcomes goal, putting the spotlight on olpasiran's Phase 3Amgen—Amgen reports six-month MARITIME Phase 3 update and issues full-year 2026 revenue guidance of $38.2B–$39.4B

Olpasiran

by AmgenUS

Prove that cutting lipoprotein(a) almost to zero prevents heart attacks and cardiac deaths, giving the first treatment for a risk factor that diet, exercise and statins do not touch.

PilotStage 3 of 5

Three Phase 3 trials running; main outcomes trial (7,297 patients) now due to complete in 2028.

Updated 8 Sep 2026Checked 11 Oct0 updates this week

Milestones

Next · OCEAN(a)-Outcomes primary completion
  1. Licensed from Arrowhead (then AMG 890)28 Sep 2016Complete.
  2. Phase 2 OCEAN(a)-DOSE: Lp(a) cut by up to ~100%Nov 2022Complete.
  3. Phase 3 OCEAN(a)-Outcomes starts14 Dec 2022Complete.
  4. Phase 3 OCEAN(a)-PreEvent starts (first-event prevention)22 Aug 2025Complete.
  5. Phase 3 OCEAN(a)-CCTA plaque trial starts23 Mar 2026Complete.
  6. OCEAN(a)-Outcomes primary completionTarget Mar 2028+15 mooriginally Dec 2026Current milestone.

Most important updates

Upcoming

  1. Mar 2028OCEAN(a)-Outcomes primary completion+15 mooriginally Dec 2026in about 72 weeks (next)
  2. Jun 2028OCEAN(a)-CCTA plaque trial estimated primary completion
Primer